These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22296584)

  • 1. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.
    Marder W; McCune WJ; Wang L; Wing JJ; Fisseha S; McConnell DS; Christman GM; Somers EC
    Gynecol Endocrinol; 2012 Aug; 28(8):624-7. PubMed ID: 22296584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
    Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A
    Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.
    Mok CC; Chan PT; To CH
    Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
    Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
    Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of ovarian reserve by serum anti-Müllerian hormone in patients with systemic lupus erythematosus: a meta-analysis.
    Luo W; Mao P; Zhang L; Chen X; Yang Z
    Ann Palliat Med; 2020 Mar; 9(2):207-215. PubMed ID: 32156138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
    Tamirou F; Husson SN; Gruson D; Debiève F; Lauwerys BR; Houssiau FA
    Arthritis Rheumatol; 2017 Jun; 69(6):1267-1271. PubMed ID: 28235250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve.
    Di Mario C; Petricca L; Gigante MR; Barini A; Barini A; Varriano V; Paglionico A; Cattani P; Ferraccioli G; Tolusso B; Gremese E
    Endocrine; 2019 Feb; 63(2):369-375. PubMed ID: 30324323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
    Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
    Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).
    Clowse ME; Copland SC; Hsieh TC; Chow SC; Hoffman GS; Merkel PA; Spiera RF; Davis JC; McCune WJ; Ytterberg SR; St Clair EW; Allen NB; Specks U; Stone JH;
    Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1777-81. PubMed ID: 22127969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease.
    Harward LE; Mitchell K; Pieper C; Copland S; Criscione-Schreiber LG; Clowse ME
    Lupus; 2013 Jan; 22(1):81-6. PubMed ID: 23263867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial].
    Gris-Martínez JM; Trillo-Urrutia L; Gómez-Cabeza JJ; Encabo-Duró G
    Med Clin (Barc); 2016 Feb; 146(3):97-103. PubMed ID: 26194532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women.
    Su HI; Maas K; Sluss PM; Chang RJ; Hall JE; Joffe H
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1961-6. PubMed ID: 24081742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone.
    Lawrenz B; Henes J; Henes M; Neunhoeffer E; Schmalzing M; Fehm T; Kïtter I
    Lupus; 2011 Oct; 20(11):1193-7. PubMed ID: 21768179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of ovarian reserve with anti-Müllerian hormone in female patients with systemic lupus erythematosus].
    Chen D; Yuan S; Zhan Z; Zhan Y; Yang X; Liang L
    Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(13):977-80. PubMed ID: 24851682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment.
    Nam HK; Kim HR; Rhie YJ; Lee KH
    J Korean Med Sci; 2017 Mar; 32(3):475-479. PubMed ID: 28145651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide.
    Morel N; Bachelot A; Chakhtoura Z; Ghillani-Dalbin P; Amoura Z; Galicier L; Aumaitre O; Piette JC; Pourrat J; Boutin D; Sacre K; Kahn JE; Duhaut P; Farge D; Francès C; Guettrot-Imbert G; Harlé JR; Lambotte O; Le Guern V; Sène D; Trad S; Vidal E; Sarrot-Reynauld F; Gompel A; Tanguy ML; Touraine P; Lacorte JM; Costedoat-Chalumeau N;
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3785-92. PubMed ID: 23833039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist.
    Hagen CP; Sørensen K; Anderson RA; Juul A
    Fertil Steril; 2012 Nov; 98(5):1326-30. PubMed ID: 22901847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with Gonadotropin Releasing Hormone Agonists in Systemic Lupus Erythematosus Patients Receiving Cyclophosphamide: A Long-term Follow-up Study.
    Orefice V; Ceccarelli F; Perrone G; Perricone C; Galoppi P; Pacucci VA; Spinelli FR; Alessandri C; Brunelli R; Conti F
    Isr Med Assoc J; 2020 Jun; 22(6):343-347. PubMed ID: 32558438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian protection with gonadotropin-releasing hormone agonists during cyclophosphamide therapy in systemic lupus erythematosus.
    Kado R; McCune WJ
    Best Pract Res Clin Obstet Gynaecol; 2020 Apr; 64():97-106. PubMed ID: 31866283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of anti-Müllerian hormone levels in premenopausal patients with systemic lupus erythematosus.
    Gasparin AA; Souza L; Siebert M; Xavier RM; Chakr RM; Palominos PE; Brenol JC; Monticielo OA
    Lupus; 2016 Mar; 25(3):227-32. PubMed ID: 26223296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.